This Viewpoint discusses the increased use of decentralized clinical trials (DCTs) to improve efficiency in health research, highlights a number of risks to research rigor inherent in DCTs, and suggests ways in which DCT designers can better frame trial monitoring and oversight to ensure data integrity and avoid health inequities.